论文部分内容阅读
我们对应用Benazepril(汽巴—嘉基制药有限公司生产)治疗的68例患者,蛋白尿的变化进行了临床研究,试图为难治性肾病的治疗寻找一安全有效的药物。 1 资料和方法 1.1 一般资料 68例均为经激素和/或免疫抑制剂常规治疗无效的原发性肾病综合征,符合1985年全国肾脏病会议修订的临床分型标准。Ⅰ型20例,Ⅱ型48例。男性39例,女29例,平均年龄32.4岁,平均病程1.4年。其中16例行肾活组织检查,膜性肾病4例,系膜增殖性肾炎3例,局灶节段硬化肾炎5例,膜增殖性肾炎4例。 1.2 治疗方法 全部患者入院后,在原服用激素和/或免疫抑制剂不变及对症处理前提下,加服Benazepril,常
We conducted a clinical study of the changes in proteinuria in 68 patients treated with Benazepril (Ciba-Geigy Pharmaceutical Co., Ltd.) in an attempt to find a safe and effective drug for the treatment of refractory kidney disease. 1 Materials and Methods 1.1 General Information 68 cases were steroid and / or immunosuppressive agents ineffective treatment of primary nephrotic syndrome, in line with the 1985 National Nephropathy Conference revision of the clinical classification criteria. 20 cases of type Ⅰ, 48 cases of type Ⅱ. There were 39 males and 29 females, with an average age of 32.4 years and an average duration of 1.4 years. 16 cases of renal biopsy, membranous nephropathy in 4 cases, 3 cases of mesangial proliferative glomerulonephritis, focal segmental sclerosis nephritis in 5 cases, 4 cases of proliferative glomerulonephritis. 1.2 Treatment All patients admitted to hospital, in the original use of hormones and / or immunosuppressive agents unchanged and symptomatic treatment premise, plus service Benazepril, often